Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group
| Autor: | Helen Goergen, Bastian von Tresckow, Michael Fuchs, Peter Borchmann, Andreas Engert, Volker Diehl, Boris Böll, Dennis A. Eichenauer, Leonard Elger, Stefanie Kreissl, Horst Müller |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male medicine.medical_specialty Medizin Disease-Free Survival 03 medical and health sciences 0302 clinical medicine immune system diseases Internal medicine hemic and lymphatic diseases Germany medicine Classical Hodgkin lymphoma Retrospective analysis Overall survival Humans Aged Retrospective Studies business.industry Incidence (epidemiology) Lymphoma Non-Hodgkin Neoplasms Second Primary Hematology Middle Aged medicine.disease Hodgkin Disease Lymphoma Survival Rate Median time 030220 oncology & carcinogenesis Hodgkin lymphoma Female business After treatment 030215 immunology Follow-Up Studies |
| Zdroj: | British journal of haematologyReferences. 193(3) |
| ISSN: | 1365-2141 |
| Popis: | Data on non-Hodgkin lymphoma (NHL) after classical Hodgkin lymphoma (cHL) are scarce. We therefore performed a retrospective analysis comprising 11·841 cHL patients who had first-line treatment within the randomized German Hodgkin Study Group (GHSG) HD7-HD15 studies. After a median follow-up of 106 months, 175 patients (1·5%) had developed NHL. The median time to NHL was 44 months, the median age at NHL diagnosis was 54 years. The five-year event-free survival and overall survival estimates from the diagnosis of NHL were 36·9% and 44·2%, respectively. Thus, NHL after cHL is a rare event primarily affecting older individuals and often resulting in the patient´s death. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text